Felix Gerhard Maria Dietlein, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fluorine Radioisotopes | 3 | 2020 | 405 | 1.210 |
Why?
|
| Glutamate Carboxypeptidase II | 2 | 2020 | 90 | 0.800 |
Why?
|
| Prostatic Neoplasms | 8 | 2021 | 11094 | 0.780 |
Why?
|
| Gallium Radioisotopes | 5 | 2021 | 195 | 0.670 |
Why?
|
| Oligopeptides | 3 | 2019 | 1195 | 0.620 |
Why?
|
| Antigens, Surface | 2 | 2020 | 1617 | 0.610 |
Why?
|
| DNA Repair | 4 | 2020 | 2050 | 0.580 |
Why?
|
| Niacinamide | 1 | 2019 | 419 | 0.570 |
Why?
|
| Urea | 2 | 2016 | 449 | 0.570 |
Why?
|
| Nucleotides | 1 | 2020 | 454 | 0.560 |
Why?
|
| Lysine | 3 | 2016 | 998 | 0.500 |
Why?
|
| Small Cell Lung Carcinoma | 4 | 2024 | 454 | 0.500 |
Why?
|
| Neoplasms | 9 | 2022 | 22350 | 0.470 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2014 | 111 | 0.440 |
Why?
|
| Organometallic Compounds | 1 | 2016 | 647 | 0.420 |
Why?
|
| Edetic Acid | 3 | 2019 | 277 | 0.400 |
Why?
|
| DNA Repair Enzymes | 1 | 2014 | 342 | 0.400 |
Why?
|
| Drug Synergism | 2 | 2018 | 1757 | 0.390 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2020 | 1536 | 0.390 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2020 | 9407 | 0.390 |
Why?
|
| Promoter Regions, Genetic | 2 | 2022 | 5795 | 0.380 |
Why?
|
| Gallium Isotopes | 3 | 2021 | 6 | 0.370 |
Why?
|
| Iodine Radioisotopes | 2 | 2024 | 1030 | 0.360 |
Why?
|
| ras Proteins | 1 | 2015 | 1055 | 0.340 |
Why?
|
| Tissue Distribution | 4 | 2024 | 2275 | 0.320 |
Why?
|
| Protein Kinases | 1 | 2015 | 1610 | 0.300 |
Why?
|
| Mutation | 7 | 2022 | 30214 | 0.300 |
Why?
|
| Computational Biology | 1 | 2020 | 3564 | 0.290 |
Why?
|
| Kallikreins | 2 | 2020 | 219 | 0.280 |
Why?
|
| Enzyme Inhibitors | 2 | 2015 | 3723 | 0.280 |
Why?
|
| Antineoplastic Agents | 5 | 2018 | 13644 | 0.270 |
Why?
|
| Signal Transduction | 7 | 2024 | 23618 | 0.270 |
Why?
|
| Prostate-Specific Antigen | 4 | 2021 | 2463 | 0.260 |
Why?
|
| Radiopharmaceuticals | 4 | 2023 | 2703 | 0.250 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2024 | 3605 | 0.240 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 2887 | 0.240 |
Why?
|
| Proteins | 1 | 2020 | 6002 | 0.240 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2018 | 258 | 0.240 |
Why?
|
| Lung Neoplasms | 8 | 2024 | 13489 | 0.230 |
Why?
|
| Kidney | 1 | 2019 | 7073 | 0.230 |
Why?
|
| Ligands | 3 | 2019 | 3274 | 0.220 |
Why?
|
| Angiopoietin-2 | 1 | 2024 | 186 | 0.210 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 4523 | 0.210 |
Why?
|
| Mice, SCID | 2 | 2024 | 2626 | 0.200 |
Why?
|
| Adenocarcinoma | 2 | 2020 | 6359 | 0.200 |
Why?
|
| Colonic Neoplasms | 1 | 2014 | 2535 | 0.190 |
Why?
|
| Cell Line, Tumor | 11 | 2024 | 17089 | 0.190 |
Why?
|
| Apoptosis | 3 | 2016 | 9514 | 0.180 |
Why?
|
| DNA Repair-Deficiency Disorders | 1 | 2020 | 37 | 0.180 |
Why?
|
| Nuclear Medicine | 1 | 2023 | 262 | 0.170 |
Why?
|
| Nuclear Proteins | 2 | 2017 | 5795 | 0.170 |
Why?
|
| Receptor, EphA2 | 1 | 2020 | 41 | 0.170 |
Why?
|
| Neurofibromin 1 | 1 | 2020 | 190 | 0.160 |
Why?
|
| Genomics | 2 | 2021 | 5922 | 0.160 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2018 | 1762 | 0.150 |
Why?
|
| Gene Fusion | 1 | 2021 | 356 | 0.150 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2020 | 2056 | 0.150 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2022 | 792 | 0.150 |
Why?
|
| Isotope Labeling | 1 | 2019 | 390 | 0.150 |
Why?
|
| Whole Body Imaging | 1 | 2019 | 283 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2020 | 547 | 0.140 |
Why?
|
| GTP Phosphohydrolases | 1 | 2020 | 525 | 0.140 |
Why?
|
| DNA Damage | 3 | 2016 | 2469 | 0.140 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 9613 | 0.130 |
Why?
|
| Serine | 1 | 2020 | 828 | 0.130 |
Why?
|
| Oncogenes | 1 | 2022 | 1232 | 0.130 |
Why?
|
| Propranolol | 1 | 2018 | 493 | 0.130 |
Why?
|
| Neuroblastoma | 1 | 2024 | 1266 | 0.130 |
Why?
|
| Humans | 34 | 2024 | 766812 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2020 | 5389 | 0.120 |
Why?
|
| Parkinsonian Disorders | 1 | 2018 | 285 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2018 | 559 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 2 | 2017 | 2823 | 0.120 |
Why?
|
| Germany | 1 | 2016 | 882 | 0.110 |
Why?
|
| Cysteine Endopeptidases | 1 | 2016 | 542 | 0.110 |
Why?
|
| DNA Mutational Analysis | 1 | 2022 | 4114 | 0.110 |
Why?
|
| Positron-Emission Tomography | 3 | 2021 | 6548 | 0.110 |
Why?
|
| Cell Survival | 2 | 2021 | 5749 | 0.110 |
Why?
|
| Cluster Analysis | 1 | 2020 | 2721 | 0.100 |
Why?
|
| Neoplasms, Experimental | 2 | 2018 | 1228 | 0.100 |
Why?
|
| Male | 15 | 2024 | 364154 | 0.100 |
Why?
|
| Androgen Antagonists | 1 | 2021 | 1411 | 0.100 |
Why?
|
| Mice | 12 | 2024 | 81898 | 0.100 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2018 | 1241 | 0.100 |
Why?
|
| Zirconium | 2 | 2023 | 109 | 0.100 |
Why?
|
| Melanoma | 2 | 2020 | 5702 | 0.090 |
Why?
|
| Neoplasm Transplantation | 1 | 2015 | 2012 | 0.090 |
Why?
|
| Radioisotopes | 2 | 2023 | 509 | 0.090 |
Why?
|
| Animals | 14 | 2024 | 168939 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2017 | 5690 | 0.090 |
Why?
|
| Stomach Neoplasms | 1 | 2020 | 1480 | 0.080 |
Why?
|
| Recurrence | 2 | 2019 | 8507 | 0.080 |
Why?
|
| Drug Design | 1 | 2014 | 1043 | 0.080 |
Why?
|
| RNA-Binding Proteins | 1 | 2018 | 1885 | 0.080 |
Why?
|
| Gene Amplification | 1 | 2013 | 1088 | 0.080 |
Why?
|
| Thyroid Neoplasms | 1 | 2022 | 2355 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2022 | 8623 | 0.080 |
Why?
|
| Liver Neoplasms | 1 | 2024 | 4356 | 0.080 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2018 | 2057 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 6105 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 3511 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 20146 | 0.070 |
Why?
|
| Neoplasm Metastasis | 3 | 2024 | 4892 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 2952 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 11218 | 0.060 |
Why?
|
| Genome | 1 | 2013 | 1753 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2022 | 4903 | 0.060 |
Why?
|
| Bayes Theorem | 1 | 2013 | 2353 | 0.060 |
Why?
|
| DNA Copy Number Variations | 1 | 2013 | 2045 | 0.060 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2024 | 122 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2024 | 3610 | 0.060 |
Why?
|
| Aged | 5 | 2020 | 171344 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 2841 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2020 | 7869 | 0.050 |
Why?
|
| Skin Neoplasms | 2 | 2020 | 5860 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 4780 | 0.050 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 18329 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 14653 | 0.050 |
Why?
|
| Platinum | 1 | 2022 | 219 | 0.050 |
Why?
|
| Genome, Human | 1 | 2014 | 4443 | 0.040 |
Why?
|
| Quinolines | 2 | 2018 | 769 | 0.040 |
Why?
|
| Prevalence | 1 | 2016 | 15835 | 0.040 |
Why?
|
| Carboplatin | 1 | 2022 | 790 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 2022 | 818 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 8045 | 0.040 |
Why?
|
| Cyclin T | 1 | 2017 | 19 | 0.040 |
Why?
|
| Middle Aged | 4 | 2019 | 223267 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2017 | 68 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 2 | 2024 | 9244 | 0.040 |
Why?
|
| Naphthalenes | 1 | 2018 | 198 | 0.040 |
Why?
|
| Azoxymethane | 1 | 2016 | 32 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 2024 | 976 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2019 | 41706 | 0.030 |
Why?
|
| Microsatellite Instability | 1 | 2020 | 726 | 0.030 |
Why?
|
| Phenylurea Compounds | 1 | 2018 | 533 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2021 | 81657 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2018 | 9546 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2019 | 1250 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 1836 | 0.030 |
Why?
|
| Intestinal Neoplasms | 1 | 2016 | 314 | 0.030 |
Why?
|
| Prostate | 1 | 2021 | 1760 | 0.030 |
Why?
|
| RNA Polymerase II | 1 | 2017 | 549 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 754 | 0.030 |
Why?
|
| Diamines | 1 | 2012 | 60 | 0.030 |
Why?
|
| Genes, myc | 1 | 2013 | 391 | 0.030 |
Why?
|
| Female | 8 | 2024 | 396532 | 0.020 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 1105 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2013 | 451 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2018 | 1188 | 0.020 |
Why?
|
| Quinazolines | 1 | 2018 | 1367 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2016 | 1007 | 0.020 |
Why?
|
| High-Throughput Screening Assays | 1 | 2017 | 938 | 0.020 |
Why?
|
| Organic Chemicals | 1 | 2012 | 211 | 0.020 |
Why?
|
| Benzothiazoles | 1 | 2012 | 244 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 21162 | 0.020 |
Why?
|
| Genetic Heterogeneity | 1 | 2013 | 735 | 0.020 |
Why?
|
| Piperidines | 1 | 2018 | 1663 | 0.020 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2016 | 882 | 0.020 |
Why?
|
| Risk Factors | 1 | 2016 | 74889 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2012 | 1647 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2015 | 3618 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2017 | 4277 | 0.020 |
Why?
|
| DNA Primers | 1 | 2012 | 2826 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2018 | 2631 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 4853 | 0.020 |
Why?
|
| Caenorhabditis elegans | 1 | 2016 | 1474 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2012 | 996 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 3942 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 18076 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2020 | 11062 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2017 | 3440 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2018 | 3043 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 4570 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2018 | 10101 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 6853 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 5330 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 7612 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 10745 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 59548 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2012 | 5890 | 0.010 |
Why?
|
| Gene Expression | 1 | 2013 | 7585 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 10263 | 0.010 |
Why?
|
| Cell Line | 1 | 2013 | 15564 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 22351 | 0.010 |
Why?
|
| Liver | 1 | 2015 | 7571 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2013 | 4050 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2017 | 12159 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 9528 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 39312 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 11876 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2021 | 54872 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2013 | 65286 | 0.000 |
Why?
|